BMS Archive

Plant · Scientific monograph

Piper methysticum

Kava / Kava-Kava

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Anxiolytic Research, Sedative Research, Phytotherapy, Psychiatry Research

Research overview

Historical use

Piper methysticum (kava or kava-kava) is indigenous to the Pacific Islands and has been cultivated and ceremonially consumed for over 3,000 years. Prepared as an aqueous extract of the dried root, kava was central to religious ceremonies, dispute resolution, and social bonding across Vanuatu, Fiji, Tonga, Hawaii, and Samoa. Pacific Island cultures recognised its anxiolytic, euphoriant, and sedative properties and used it therapeutically for anxiety, insomnia, pain, and urinary tract infections. It was introduced to European phytomedicine in the 1980s, and several European countries licensed kava preparations for anxiety before hepatotoxicity reports triggered regulatory restrictions.

Modern research context

Kava has among the strongest evidence bases of any herbal medicine for anxiety. A 2022 systematic review of 12 clinical trials found significant anxiolytic efficacy for generalized anxiety disorder (GAD) and situational anxiety [1], with effect sizes in the moderate range. Note: comparisons to benzodiazepine effect sizes are approximate and should not be interpreted as therapeutic equivalence to prescribed anxiolytic regimens. A high-quality double-blind RCT by Sarris et al. found significant reduction in GAD symptoms with standardized aqueous kava extract compared to placebo after 6 weeks [3]. A 2000 systematic review and meta-analysis (Pittler and Ernst) established Level A evidence for kava in anxiety [6]; subsequent RCTs including the Sarris et al. 2020 double-blind trial [3] have broadly replicated these findings. The critical safety issue is hepatotoxicity, which has complicated clinical use. Evidence suggests hepatotoxicity risk is substantially higher with acetone/ethanol extracts than with traditional aqueous preparations; this distinction has informed partial re-licensing in some jurisdictions.

Adverse effects

HEPATOTOXICITY is the major clinical concern: case reports of serious drug-induced liver injury (DILI), including acute liver failure requiring transplantation and fatalities, have been documented, primarily with non-aqueous (ethanolic/acetone) extracts [2, 4]. Traditional aqueous extracts appear to carry substantially lower hepatotoxicity risk. Dermopathy (pelargoniedermatopathy) — a reversible scaly skin condition with yellowish discolouration — occurs with heavy, prolonged use. Sedation and cognitive impairment at higher doses. Heavy or long-term use impairs driving ability. Rare movement disorder (extrapyramidal effects) reported. Risk of dependence with daily use.

Contraindications

Active or history of liver disease — contraindicated with all kava preparations. Concurrent hepatotoxic medications (statins at high dose, azole antifungals, methotrexate, paracetamol at high doses) — additive hepatotoxicity risk. Concurrent alcohol use — increases metabolic activation of potentially hepatotoxic metabolites. Benzodiazepines, barbiturates, opioids — additive CNS depression. Driving or operating machinery — significant impairment at therapeutic doses. Pregnancy and lactation. Parkinson's disease — may worsen extrapyramidal symptoms. Age under 18 years.

Clinical and phytochemical data

Used part

Peeled and dried root and rhizome. Traditional aqueous extraction (water-based) is the preferred preparation; pharmacological preparations use standardized ethanolic or aqueous-acetone extracts. Extraction solvent significantly affects kavalactone profile and hepatotoxicity risk.

Primary active compounds

  • Kavain (kawain) — primary kavalactone; anxiolytic via sodium channel blockade

  • Dihydrokavain — sedative kavalactone

  • Methysticin — antiseizure activity; CYP1A2 inducer

  • Dihydromethysticin — anxiolytic, analgesic

  • Yangonin — cannabinoid CB1 receptor agonist

  • Desmethoxyyangonin — MAO-B inhibitor

Mechanism of action

Kavalactones exert anxiolytic and sedative effects through multiple CNS mechanisms distinct from benzodiazepines. Kavain and dihydrokavain are positive allosteric modulators at GABA-A receptors, enhancing chloride channel conductance without direct benzodiazepine site binding, explaining the slower tolerance development compared to benzodiazepines [1, 2]. Kavalactones block voltage-gated sodium channels (Nav) and calcium channels (VGCC), reducing neuronal excitability and neurotransmitter release. Yangonin is an agonist at cannabinoid CB1 receptors, contributing to the euphoriant and anxiolytic profile [2]. Desmethoxyyangonin inhibits MAO-B, mildly elevating dopaminergic tone. Kavain also modulates 5-HT1A serotonin receptors as a partial agonist. The hepatotoxicity mechanism likely involves CYP450-mediated formation of reactive metabolites, or direct mitochondrial membrane disruption by kavalactones at high hepatic concentrations.

Pharmacokinetics

Absorption

Kavain oral bioavailability is moderate (~20-40%); fat-rich meals enhance absorption given kavalactone lipophilicity. Tmax approximately 1.8 hours for kavain following oral dose of standardized extract. Traditional kava beverage produces lower and slower peak plasma concentrations than encapsulated extracts. Significant variability exists between preparations.

Distribution

Kavalactones are highly lipophilic and accumulate in CNS and liver. Plasma protein binding for kavain approximately 90%. Volume of distribution is large, consistent with extensive tissue distribution. CNS entry is rapid, explaining the fast onset of sedation.

Metabolism

Hepatic metabolism via CYP1A2, CYP2C9, CYP2C19, and CYP3A4. Kavalactones inhibit multiple CYP isoforms including CYP2C9, CYP2C19, and CYP3A4 in vitro; clinical significance at standard oral kavalactone doses requires verification in formal human pharmacokinetic interaction studies, though drug interaction caution is warranted given in vitro potency at concentrations potentially achievable in vivo [5]. Methysticin induces CYP1A2. Piperine (minor constituent) inhibits P-glycoprotein. Metabolic activation of certain kava constituents may produce hepatotoxic reactive intermediates particularly with ethanol co-administration.

Excretion

Kavalactones and their hydroxylated, demethylated, and reduced metabolites are excreted renally and in faeces. t1/2 of kavain approximately 9 hours. Kavalactones undergo significant enterohepatic recirculation of glucuronide metabolites.

Safety and interactions

Drug interactions

Alcohol: additive CNS depression AND increased hepatotoxicity risk via metabolic activation — absolute contraindication to combine [2]. Benzodiazepines, opioids, barbiturates, CNS depressants: additive sedation and respiratory depression risk. CYP2C9 substrates (warfarin, phenytoin, NSAIDs): kavalactone CYP2C9 inhibition may increase plasma levels — monitor INR closely with warfarin. CYP3A4 substrates: inhibition may elevate plasma levels of concomitant drugs. Levodopa and dopaminergic drugs: kavalactones may reduce dopamine availability — potential adverse interaction in Parkinson's disease patients. Hepatotoxic medications (high-dose statins, azole antifungals, methotrexate): additive hepatotoxicity risk — avoid combination.

Toxicity

Hepatotoxicity is the primary toxicological concern. Regulatory agencies including the German BfArM, UK MHRA, Canadian Health Canada, and US FDA have all issued warnings or restrictions based on case reports. Compiled reports document over 100 cases of serious liver injury attributable to kava preparations globally, including deaths and transplantations. The hepatotoxicity rate has been estimated at approximately 1 in 60–125 million daily doses for standard preparations — rare but serious [source for this specific pharmacovigilance estimate requires citation; likely Teschke et al. regulatory analyses — PMID verification required]. Traditional aqueous kava preparations used by Pacific Islander communities at cultural doses have a markedly lower hepatotoxicity record, supporting the importance of extraction method. Dermopathy with prolonged high-dose use is reversible on cessation.

Special precautions

Pregnancy

Contraindicated during pregnancy. Kavalactones cross the placenta in animal studies. Traditional Pacific Island communities generally excluded pregnant women from kava consumption. Insufficient and no controlled human data available. Evidence basis: traditional contraindication; animal data.

Lactation

Contraindicated. Kavalactones are lipophilic and likely excreted in breast milk. No human data. Risk of infant CNS depression.

Hepatic impairment

Contraindicated in any degree of hepatic impairment. Baseline liver function tests should be obtained before starting kava even in healthy individuals; monitoring every 4-8 weeks recommended during use.

Renal impairment

Kavalactone metabolites are partially renally excreted. No formal PK studies in renal impairment. Given primary hepatic metabolism and hepatotoxicity concern, renal impairment is a secondary consideration; use with caution and preference for lower doses.

Sources and references

  1. [1] - Smith K, Leiras C, "The effectiveness and safety of kava kava for treating anxiety symptoms", World J Biol Psychiatry, 2022, PMID: 35311615
  2. [2] - Bian T et al., "Kava as a clinical nutrient: promises and challenges", Pharmacol Res, 2022, PMID: 35378276
  3. [3] - Sarris J et al., "Kava for generalized anxiety disorder: a double blind RCT", BMC Psychiatry, 2020, PMID: 31948424
  4. [4] - Ulbricht C, "Kava: an evidence-based systematic review", Am Fam Physician, 2017, PMID: 28762712
  5. [5] - Izzo AA, Ernst E, "Interactions between herbal medicines and prescribed drugs", Drugs, 2009, PMID: 19719333
  6. [6] - Pittler MH, Ernst E, "Efficacy of kava extract for treating anxiety: systematic review and meta-analysis", J Clin Psychopharmacol, 2000, PMID: 10711427

Additional source links

Continue browsing